Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients
- 1 October 2001
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 38 (4) , S11-S15
- https://doi.org/10.1053/ajkd.2001.27505
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- PREDNISONE WITHDRAWAL IN KIDNEY TRANSPLANT RECIPIENTS ON CYCLOSPORINE AND MYCOPHENOLATE MOFETIL-A PROSPECTIVE RANDOMIZED STUDY1,2Transplantation, 1999
- RENAL ALLOGRAFT SURVIVAL IN AFRICAN-AMERICANS: INFLUENCE OF THE DUFFY BLOOD GROUP.Transplantation, 1999
- Transforming growth factor-β1 hyperexpression in African American end-stage renal disease patientsKidney International, 1998
- RACIAL DIFFERENCES IN RENAL TRANSPLANTATION AFTER IMMUNOSUPPRESSION WITH TACROLIMUS VERSUS CYCLOSPORINE1Transplantation, 1998
- IMMUNOSUPPRESSIVE THERAPY IN HIGH-RISK TRANSPLANT PATIENTSTransplantation, 1997
- Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejectionKidney International, 1995
- Racial differences in renal allograft survival: The role of systemic hypertensionKidney International, 1995
- WITHDRAWAL OF STEROIDS AFTER RENAL TRANSPLANTATION—CLINICAL PREDICTORS OF OUTCOME1Transplantation, 1992
- POSSIBLE CONTRIBUTION OF PRETRANSPLANT IMMUNE RESPONDER STATUS TO RENAL ALLOGRAFT SURVIVAL DIFFERENCES OF BLACK VERSUS WHITE RECIPIENTSTransplantation, 1991